Drug intelligence / Profile preview

BEBT-738

Development stage: Preclinical
Lead developer: BeBetter Med
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

BEBT-738 is a kidney-targeted oligonucleotide developed by Guangzhuo BeBetter Medicine Technology for the treatment of diabetes. Utilizing the company's proprietary POC-kidney platform, the drug is designed to specifically target renal tissues to reduce the expression or function of Sodium/glucose cotransporter 2 (SGLT2). By inhibiting SGLT2, BEBT-738 aims to lower glucose reabsorption in the proximal tubules of the kidney, thereby promoting glucose excretion in the urine and improving glycemic control in patients with diabetes. The drug is currently in the preclinical stage of development.

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on BEBT-738.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEBT-738.

Explore the full profile